FDA Plan Could Put Pharma Ads Out Of Reach For Broadcasters.

The Trump administration intends to push forward with new advertising restrictions on the pharmaceutical industry. A notice has been issued saying that the Food and Drug Administration will move in the coming months to effectively eliminate the option for prescription drug advertisements broadcast through media such as radio or television.

“The proliferation of direct-to-consumer (DTC) advertising across television and digital platforms has created potential patient confusion and harm from inappropriate demand for medications,” the Office of Management and Budget alert says. The group blames those ads for “distorting” the doctor-patient relationship and a “misallocation of healthcare resources and government overspending” on prescription drugs.

Specifics of the plans haven’t been released. However, the outline says the FDA will propose revising the prescription drug advertising regulation to require radio and TV ads to disclose all relevant risk and safety information to consumers within the confines of the ad itself rather than referring consumers to an external source like a dedicated website. The net effect would be to make it near-impossible for pharmaceutical companies to use broadcast advertising because of the sheer length of time it would take to list all of the warnings that accompany most drugs.

In a move that seems designed to navigate expected First Amendment legal challenges by drug makers and broadcasters, the OMB says the pending action will not constitute an outright ban on DTC drug advertising. It would instead require “complete and accurate safety, contraindication, and other risk information” in the drug advertisements. The administration says the move wouldn’t be to limit companies’ free speech, but rather to ensure “that patients and consumers can make fully informed decisions.”

Part Of ‘MAHA’ Effort

The crackdown on prescription drug advertising has been brewing for more than a year. President Trump signed an executive memo last year directing federal agencies to step up their enforcement to ensure prescription drug advertising laws are being followed. The memo also directed the Department of Health and Human Services and the FDA to “take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements, to the extent permitted by applicable law.”

The result is the plan to remove the “adequate provision” loophole in the FDA’s rules, which has allowed the disclosure of side effect information in a location other than the commercial itself including 1-800 numbers, print inserts, and websites.

Any potential ban would have a bigger impact on TV, where iSpot.tv says more than $7 billion of drug ads aired in 2025. But radio is also an outlet that big drug makers leverage. Among stations tracked by Media Monitors, Johnson & Johnson’s Tremfya ranked as the seventh-biggest national advertiser last week. And prescription drug ads totaled just under 85,000.

The Pharmaceutical Research and Manufacturers of America (PhRMA) has defended DTC ads as a way to provide patients with important fact-based, useful and accessible information about potential treatment options. “PhRMA’s member companies are committed to responsible, accurate advertising that helps Americans make informed decisions about their health care in consultation with their doctor,” the trade group said in a statement.

But HHS Secretary Robert F. Kennedy Jr. has been critical of broadcast ads for prescription drugs and has repeatedly said he supports ending DTC ads altogether. Kennedy has said that getting them off the air part of the administration’s “Make America Healthy Again” initiative. “Pharmaceutical ads hooked this country on prescription drugs,” Kennedy said last year.